Hemophilia B - Market Insights, Epidemiology and Market Forecast - 2025

  • ID: 4410571
  • Drug Pipelines
  • 70 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 3
“Hemophilia B - Market Insights, Epidemiology and Market Forecast - 2025” report provides an overview of the disease and in depth research related to Hemophilia B for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Hemophilia B . It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Hemophilia B for 7 major markets.

The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, The report highlights the frontrunners, the drivers and barriers for the Hemophilia B market, as well as treatment algorithm, current treatments & advancements are included. The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Hemophilia B , providing an in-depth analysis of emerging therapies which will create an impact through their launch.

According to this research, the forecasted patient population of Hemophilia B for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Hemophilia B 7MM market size is estimated to be USD XX by 2025. The report will help in enhanced understanding of the Hemophilia B market from inside out, with transparency into the calculated patient forecasting data and estimated market size.

Key Coverage
  • Understanding historical and forecasted epidemiological data for Hemophilia B covering 7MM from 2015-2025.
  • Segment level epidemiology and market split for Hemophilia B .
  • The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Hemophilia B .
  • The report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Hemophilia B market trends.
  • Thorough market distribution based on market share for Hemophilia B .
Reasons to buy
  • The report will help in developing business strategies by understanding trends shaping and driving the Hemophilia B market.
  • To understand the future market competition in the Hemophilia B market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Hemophilia B in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
Note: Please allow up to 48 hours for delivery once payment is received.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Report Introduction

2. Hemophilia B Market Overview at a Glance
2.1. Total Market Share Distribution of Hemophilia B for 7 MM in 2016
2.2. Total Market Share Distribution of Hemophilia B for 7 MM in 2025

3. Hemophilia B
3.1.1. Overview
3.1.2. Symptoms
3.1.3. Pathophysiology
3.1.4. Staging
3.1.5. Diagnosis
3.1.6. Treatment

4. Epidemiology and Patient Population
4.1.1. United States
4.1.1.1. Diagnosed Cases of Hemophilia B in United States
4.1.2. Germany
4.1.2.1. Diagnosed Cases of Hemophilia B in Germany
4.1.3. France
4.1.3.1. Diagnosed Cases of Hemophilia B in France
4.1.4. Italy
4.1.4.1. Diagnosed Cases of Hemophilia B in Italy
4.1.5. Spain
4.1.5.1. Diagnosed Cases of Hemophilia B in Spain
4.1.6. United Kingdom
4.1.6.1. Diagnosed Cases of Hemophilia B in United Kingdom

5. Treatment Algorithm
5.1.1. Treatment Guidelines/Practices

6. Marketed Drugs for Hemophilia B
6.1. Drug 1: Company A
6.1.1. Drug Description
6.1.2. Mechanism of Action
6.1.3. Regulatory Milestones
6.1.4. Advantages & Disadvantages
6.1.5. Safety and Efficacy
6.1.6. Product Profile
6.1.7. Patent Status
6.2. Drug 2: Company B
6.2.1. Drug Description
6.2.2. Mechanism of Action
6.2.3. Regulatory Milestones
6.2.4. Advantages & Disadvantages
6.2.5. Safety and Efficacy
6.2.6. Product Profile
6.2.7. Patent Status

7. Emerging Therapies
7.1. Drug 3: Company C
7.1.1. Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Product Profile
7.1.5. Launch Date
7.1.6. Clinical Development
7.1.7. Clinical Pipeline Activity
7.1.8. Ongoing Trials Information
7.1.9. Clinical Trial by Phase
7.2. Drug 4: Company B
7.2.1. Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Product Profile
7.2.5. Launch Date
7.2.6. Clinical Development
7.2.7. Clinical Pipeline Activity
7.2.8. Ongoing Trials Information
7.2.9. Clinical Trial by Phase

8. Overview of Total Hemophilia B Market (2016 & 2025)

9. Hemophilia B: Country-Wise Market Analysis
9.1. United States
9.1.1. Historical Market Size (2015-2016)
9.1.2. Forecasted Market Size (2017-2025)
9.2. Germany Market Size
9.2.1. Historical Market Size (2015-2016)
9.2.2. Forecasted Market Size (2017-2025)
9.3. France Market Size
9.3.1. Historical Market Size (2015-2016)
9.3.2. Forecasted Market Size (2017-2025)
9.4. United Kingdom Market Size
9.4.1. Historical Market Size (2015-2016)
9.4.2. Forecasted Market Size (2017-2025)
9.5. Spain Market Size
9.5.1. Historical Market Size (2015-2016)
9.5.2. Forecasted Market Size (2017-2025)
9.6. Italy Market Size
9.6.1. Historical Market Size (2015-2016)
9.6.2. Forecasted Market Size (2017-2025)
9.7. Japan Market Size
9.7.1. Historical Market Size (2015-2016)
9.7.2. Forecasted Market Size (2017-2025)

10. Market Drivers

11. Market Restraints

12. Appendix

13. Report Methodology

14. Consulting Services

15. Disclaimer

16. About

List of Tables
Table 1: Diagnosed Cases Hemophilia B in United States (2015-2025)
Table 2: Diagnosed Cases Hemophilia B in Germany (2015-2025)
Table 3: Diagnosed Cases Hemophilia B in France (2015-2025)
Table 4: Diagnosed Cases Hemophilia B in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Hemophilia B in Spain (2015-2025)
Table 6: Diagnosed Cases Hemophilia B in Italy (2015-2025)
Table 7: Diagnosed Cases Hemophilia B in Japan (2015-2025)
Table 8: List of Marketed Drugs for Hemophilia B
Table 9: List of Pipeline Phase III Drugs for Hemophilia B
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Hemophilia B in USD, Million (2015-2025)
Table 17: Germany Market Size of Hemophilia B in USD, Million (2015-2025)
Table 18: France Market Size of Hemophilia B in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Hemophilia B in USD, Million (2015-2025)
Table 20: Spain Market Size of Hemophilia B in USD, Million (2015-2025)
Table 21: Italy Market Size of Hemophilia B in USD, Million (2015-2025)
Table 22: Japan Market Size of Hemophilia B in USD, Million (2015-2025)

List of Figures
Figure 1: Diagnosed Cases Hemophilia B in United States (2015-2025)
Figure 2: Diagnosed Cases Hemophilia B in Germany (2015-2025)
Figure 3: Diagnosed Cases Hemophilia B in France (2015-2025)
Figure 4: Diagnosed Cases Hemophilia B in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Hemophilia B in Spain (2015-2025)
Figure 6: Diagnosed Cases Hemophilia B in Italy (2015-2025)
Figure 7: Diagnosed Cases Hemophilia B in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Hemophilia B
Figure 9: List of Pipeline Phase III Drugs for Hemophilia B
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Hemophilia B in USD, Million (2015-2025)
Figure 17: Germany Market Size of Hemophilia B in USD, Million (2015-2025)
Figure 18: France Market Size of Hemophilia B in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Hemophilia B in USD, Million (2015-2025)
Figure 20: Spain Market Size of Hemophilia B in USD, Million (2015-2025)
Figure 21: Italy Market Size of Hemophilia B in USD, Million (2015-2025)
Figure 22: Japan Market Size of Hemophilia B in USD, Million (2015-2025)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll